abstract |
The present disclosure relates broadly to the field of cancer immunotherapy. For example, the present disclosure is generally a binding molecule comprising an antibody variable light chain (VL) region, variable heavy chain (VH) region, constant heavy chain 1 (CH1) region and light chain constant (CL) region. These regions are configured to form two antigen-binding Fab regions and an antigen-binding Fv region, and thus relate to binding molecules that bind to two different antigens. |